STTK

Shattuck Labs, Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001680367
$4.94 +18.18% $378.8M
Insider Selling Cluster (2 insiders)9 New Institutional Positions
Vol
Market Cap$378.8M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Inst. Holders35 funds
Inst. Value$96.0M
Inst. Activity9 buys / 2 sells
Insider Activity1B / 2S
Insider Net $$37.5K
SEC Reports12
Press Releases2
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001680367·Prev Close $4.18

Recent Activity

Jun 11, 2026 SEC
Shattuck Labs closed a $75M underwritten public offering of 10.9M common shares and 7.9M pre-funded warrants at $4.00/sh
8-K — Impact 6/10
Jun 11, 2026 SEC
This 13F institutional cluster for Shattuck Labs (STTK) reveals one mega-passive buyer (Bank of America doubling a tiny
INST-CLUSTER — Impact 4/10
Jun 11, 2026 SEC
Shattuck Labs is conducting a $75M underwritten public offering of 10.9M common shares and 7.9M pre-funded warrants at $
424B5 — Impact 6/10
Jun 10, 2026 offering
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
<p>AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuc
Jun 9, 2026 Insider
SIEGALL CLAY B bought 62,500 shares
Director @ $4.00 ($250.0K)
Jun 8, 2026 Insider
Ashiya Mona acquired 15,366,490 shares
Director
Jun 8, 2026 Insider
Ashiya Mona disposed of 15,366,490 shares
Director
Inst.
ADAGE CAPITAL PARTNERS GP, — TRIM
4,644,957 shares ($29.9M)

Price Targets

$14.83 +200.3% upside Strong Buy
Current $4.94 Low $10.00 Median $16.00 High $18.00 6 analysts
$10.00 $18.00

Analyst Ratings

Strong Buy86% buy · 14 analysts
3Strong Buy
9Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
Jun 9, 2026 Citigroup MAINTAIN Buy → Buy
Jun 8, 2026 Needham MAINTAIN Buy → Buy
Jun 8, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Jun 5, 2026 Citigroup UPGRADE Neutral → Buy
May 8, 2026 Wedbush MAINTAIN Outperform → Outperform

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.13 ▲ +3.9% $-0.18 — $-0.09 45% YoY 7
Next Q $-0.12 ▲ +4.3% $-0.21 — $-0.08 12% YoY 7
Current FY $-0.50 ▼ -8.2% $-0.79 — $-0.38 28% YoY 7
Next FY $-0.52 ▼ -0.8% $-0.88 — $-0.34 -3% YoY 7

Top Institutional Holders

FundValueMove
ROYAL BANK OF CANADATRIM
ADAGE CAPITAL PARTNERS GP,$29.9MTRIM
VANGUARD CAPITAL MANAGEMENT LLC$14.6M
Point72 Asset Management, L.P.$6.6M
AMERIPRISE FINANCIAL INC$5.8MDOUBLED

Recent Insider Trades

DateInsiderTypeValue
Jun 9, 2026SIEGALL CLAYBUY$250.0K
Jun 8, 2026Ashiya MonaC$0.00
Jun 8, 2026Ashiya MonaC$0.00
Jun 8, 2026ORBIMED ADVISORSC$0.00
Jun 8, 2026ORBIMED ADVISORSC$0.00
35 institutional holders with $96.0M total value (16,800,484 shares) as of 2026-Q1. Top holders: ROYAL, ADAGE, VANGUARD. Net buying activity: 9 institutions added/increased vs 2 reduced.

Top Institutional Holders — 2026-Q1

#FundSharesValue% of TrackedLast Move
1ROYAL BANK OF CANADA73$0.000.0%TRIM -47.2%
2ADAGE CAPITAL PARTNERS GP, L.L.C.4,644,957$29.9M31.1%TRIM -26.3%
3VANGUARD CAPITAL MANAGEMENT LLC2,277,176$14.6M15.3%
4Point72 Asset Management, L.P.1,031,049$6.6M6.9%
5AMERIPRISE FINANCIAL INC905,707$5.8M6.1%DOUBLED +7775.7%
6SUSQUEHANNA INTERNATIONAL GROUP, LLP715,965$4.6M4.8%
7RENAISSANCE TECHNOLOGIES LLC604,500$3.9M4.0%ADD +77.4%
8MARSHALL WACE, LLP581,471$3.7M3.9%TRIM -25.4%
9BlackRock, Inc.510,806$3.3M3.4%TRIM -53.3%
10FMR LLC392,500$2.5M2.6%DOUBLED +11560.2%
11TD ASSET MANAGEMENT INC382,648$2.5M2.6%ADD +52.4%
12VANGUARD FIDUCIARY TRUST CO324,588$2.1M2.2%
13TWO SIGMA INVESTMENTS, LP316,012$2.0M2.1%DOUBLED +431.1%
14STATE STREET CORP263,768$1.7M1.8%NEAR_EXIT -77.4%
15Hudson Bay Capital Management LP228,817$1.5M1.5%
16MORGAN STANLEY200,136$1.3M1.3%DOUBLED +1005.2%
17DEUTSCHE BANK AG\194,773$1.3M1.3%
18GOLDMAN SACHS GROUP INC191,442$1.2M1.3%
19DIMENSIONAL FUND ADVISORS LP155,642$1.0M1.0%DOUBLED +571.1%
20CITADEL ADVISORS LLC148,021$951.8K1.0%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
ADAGE CAPITAL PARTNERS GP, L.L.C.TRIM6,306,1274,644,957-26.3%$29.9M2026-Q1
AMERIPRISE FINANCIAL INCDOUBLED11,500905,707+7775.7%$5.8M2026-Q1
RENAISSANCE TECHNOLOGIES LLCADD340,700604,500+77.4%$3.9M2026-Q1
TD ASSET MANAGEMENT INCADD251,050382,648+52.4%$2.5M2026-Q1
MORGAN STANLEYDOUBLED18,108200,136+1005.2%$1.3M2026-Q1
DIMENSIONAL FUND ADVISORS LPDOUBLED23,192155,642+571.1%$1.0M2026-Q1
Connor, Clark & Lunn Investment Management Ltd.DOUBLED65,734139,304+111.9%$895.7K2026-Q1
BANK OF AMERICA CORP /DE/NEAR_EXIT1,106,61779,924-92.8%$513.9K2026-Q1
CHARLES SCHWAB INVESTMENT MANAGEMENT INCADD20,88140,881+95.8%$262.9K2026-Q1
Invesco Ltd.ADD28,23136,932+30.8%$237.5K2026-Q1
OMERS ADMINISTRATION CorpADD26,50033,300+25.7%$214.1K2026-Q1
CWM, LLCTRIM12743-66.1%2025-Q4
MARSHALL WACE, LLPTRIM656,653489,912-25.4%$1.8M2025-Q4
FMR LLCDOUBLED3,367392,600+11560.2%$1.4M2025-Q4
RENAISSANCE TECHNOLOGIES LLCADD216,867340,700+57.1%$1.2M2025-Q4
CWM, LLCNEAR_EXIT2,989127-95.8%2025-Q3
ADAGE CAPITAL PARTNERS GP, L.L.C.ADD4,675,0006,306,127+34.9%$15.1M2025-Q3
BANK OF AMERICA CORP /DE/DOUBLED36,8911,131,888+2968.2%$2.7M2025-Q3
BlackRock, Inc.TRIM881,388411,292-53.3%$983.0K2025-Q3
TWO SIGMA INVESTMENTS, LPDOUBLED76,934408,598+431.1%$976.5K2025-Q3
RENAISSANCE TECHNOLOGIES LLCDOUBLED38,100216,867+469.2%$518.3K2025-Q3
BARCLAYS PLCDOUBLED2,11454,311+2469.1%$189.5K2025-Q3
MORGAN STANLEYTRIM24,08816,651-30.9%$39.8K2025-Q3
FMR LLCTRIM8,4383,367-60.1%$8.0K2025-Q3
UBS Group AGNEAR_EXIT268,3711,433-99.5%$3.4K2025-Q3
12 unique insiders with 25 transactions. Net insider value: $37.5K ($250.0K bought, $212.5K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jun 9, 2026SIEGALL CLAY BDirectorBUY62,500$4.00$250.0K
Jun 8, 2026Ashiya MonaDirectorCONVERT15,366,490
Jun 8, 2026Ashiya MonaDirectorCONVERT15,366,490
Jun 8, 2026ORBIMED ADVISORS LLCDirectorCONVERT15,366,490
Jun 8, 2026ORBIMED ADVISORS LLCDirectorCONVERT15,366,490
May 29, 2026Ashiya MonaDirectorAWARD81,000
May 29, 2026SIEGALL CLAY BDirectorAWARD81,000
May 29, 2026Golumbeski GeorgeDirectorAWARD81,000
May 29, 2026Gibson Neil WDirectorAWARD81,000
May 29, 2026Baker Daniel G.DirectorAWARD81,000
May 29, 2026Boudreau Helen MDirectorAWARD81,000
May 22, 2026SIEGALL CLAY BDirectorEXERCISE128,054
May 22, 2026SIEGALL CLAY BDirectorAWARD128,054$1.08$138.9K
May 21, 2026Shukla Abhinav A.Chief Technical OfficerEXERCISE5,122
May 21, 2026Shukla Abhinav A.Chief Technical OfficerAWARD5,122$1.08$5.6K
May 15, 2026Stout StephenSee RemarksAWARD12,805$1.08$13.9K
May 15, 2026Stout StephenSee RemarksEXERCISE12,805
May 12, 2026Schreiber TaylorChief Executive OfficerAWARD25,610$1.08$27.8K
May 12, 2026Schreiber TaylorChief Executive OfficerEXERCISE25,610
May 12, 2026Pandite Arundathy N.Chief Medical OfficerSELL30,000$6.61$198.3K
May 12, 2026Shukla Abhinav A.Chief Technical OfficerEXERCISE2,032$3.57$7.3K
May 12, 2026Shukla Abhinav A.Chief Technical OfficerSELL2,032$7.01$14.2K
May 12, 2026Neill Andrew RChief Financial OfficerAWARD64,027$1.08$69.4K
May 12, 2026Neill Andrew RChief Financial OfficerEXERCISE64,027
May 10, 2026Stout StephenSee RemarksTAX W/H968$6.85$6.6K
12 SEC filing reports analyzed. Sentiment: 2 bullish, 4 bearish, 0 mixed, 6 neutral. Avg impact: 4.4/10.
BEARISH 8-K 6/10
Shattuck Labs closed a $75M underwritten public offering of 10.9M common shares and 7.9M pre-funded
Jun 11, 2026
BEARISH INST-CLUSTER 4/10
This 13F institutional cluster for Shattuck Labs (STTK) reveals one mega-passive buyer (Bank of Amer
Jun 11, 2026
BEARISH 424B5 6/10
Shattuck Labs is conducting a $75M underwritten public offering of 10.9M common shares and 7.9M pre-
Jun 11, 2026
BEARISH 424B5 6/10
Shattuck Labs filed a preliminary prospectus supplement for an underwritten public offering of commo
Jun 9, 2026
BULLISH 8-K 6/10
Shattuck Labs announced positive Phase 1 data for SL-325 (DR3 blocking antibody) showing low immunog
Jun 9, 2026
NEUTRAL 8-K 3/10
Shattuck Labs held its 2026 Annual Meeting on May 28, 2026. Stockholders approved an amendment and r
Jun 2, 2026
NEUTRAL CLUSTER 3/10
Two STTK insiders (CMO and CTO) sold a combined $212K in open-market sales on May 12, 2026, followin
May 18, 2026
NEUTRAL CLUSTER 3/10
Two senior executives at Shattuck Labs (CMO and CTO) sold a combined $212K in open-market shares on
May 15, 2026
NEUTRAL 8-K 3/10
Shattuck Labs reported Q1 2026 net loss of $0.13 per share, slightly better than consensus of -$0.14
May 7, 2026
BULLISH PRESS-RELEASE 5/10
Shattuck Labs reported Q1 2026 EPS of -$0.12, beating consensus of -$0.13 by 9.1%, with zero revenue
May 7, 2026
NEUTRAL DEFA14A 3/10
Shattuck Labs is holding its annual shareholder meeting to vote on director elections, auditor ratif
Apr 8, 2026
NEUTRAL 8-K 5/10
Shattuck Labs reported full-year 2025 financial results showing reduced net loss of $48.8 million (d
Mar 5, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 3 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$14.83 mean target +200.3% upside Strong Buy (1.25)
$10.00 Low $18.00 High
MetricValue
Current Price$4.94
Target Low$10.00
Target Mean$14.83
Target Median$16.00
Target High$18.00
# Analysts6
RecommendationStrong Buy (1.25)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
$-0.13 $-0.18 $-0.09 45.1% +3.9% 1↑ 1↓ $0.0B 0.0% 7
Next Q
2026-09-30
$-0.12 $-0.21 $-0.08 11.7% +4.3% 1↑ 1↓ $0.0B -100.0% 7
Current FY
2026-12-31
$-0.50 $-0.79 $-0.38 28.5% -8.2% 0↑ 3↓ $0.0B -100.0% 7
Next FY
2027-12-31
$-0.52 $-0.88 $-0.34 -3.0% -0.8% 0↑ 1↓ $0.0B 0.0% 7

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.132
7d ago$-0.137+0.005
30d ago$-0.137+0.005
60d ago$-0.128-0.004
90d ago$-0.128-0.004
6 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 9, 2026 Citigroup MAINTAIN Buy Buy
Jun 8, 2026 Needham MAINTAIN Buy Buy
Jun 8, 2026 HC Wainwright & Co. REITERATE Buy Buy
Jun 5, 2026 Citigroup UPGRADE Neutral Buy
May 8, 2026 Wedbush MAINTAIN Outperform Outperform
Apr 27, 2026 Cantor Fitzgerald INITIATE Overweight
Apr 20, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Mar 13, 2026 Citigroup MAINTAIN Neutral Neutral
Mar 6, 2026 Wedbush MAINTAIN Outperform Outperform
Jan 28, 2026 Piper Sandler INITIATE Overweight
Jan 6, 2026 Citigroup MAINTAIN Neutral Neutral

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263920086%
May 1, 20263920086%
Apr 1, 20263820085%
Mar 1, 20263730077%
Feb 1, 20263730077%
Jan 1, 20263630075%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 10, 2026
offering
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
<p>AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-st
Jun 9, 2026
offering
Shattuck Labs, Inc. Announces Proposed Public Offering
<p>AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-st
Jun 8, 2026
other
Shattuck Labs Announces Phase 1 Results for SL-325
<p>AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biote
Jun 8, 2026
short_volume
Short Volume: STTK — 61.6% short (1.4M / 2.2M)
Short: 1,375,886 | Exempt: 80,307 | TRF Vol: 2,233,648 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
routine
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
<p align="left">AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage bi
May 13, 2026
earnings_calendar
STTK Q1 2026 Earnings Scheduled — 2026-05-13
May 7, 2026
earnings
Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
<p align="justify">AUSTIN, Texas and DURHAM, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a
May 4, 2026
earnings_calendar
STTK Q1 2026 Earnings Scheduled — 2026-05-04
Apr 29, 2026
earnings_calendar
STTK Q1 2026 Earnings Scheduled — 2026-04-29
Mar 17, 2026
earnings_calendar
STTK Q4 2025 Earnings After Market Close — 2026-03-17
Mar 5, 2026
earnings
Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights
<p align="justify">AUSTIN, Texas and DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK),